UAE becomes second country to approve gene therapy Itvisma for spinal muscular atrophy

The UAE has become the second country worldwide to approve Itvisma, a groundbreaking gene therapy for spinal muscular atrophy ...

Minaris and Cell and Gene Therapy Catapult Announce Collaboration to Advance Delivery Methods for Cell and Gene Therapies

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...
MIT Technology Review

This company is developing gene therapies for muscle growth, erectile dysfunction, and “radical longevity”

A small group of volunteers will receive multiple injections of the experimental treatments next month, says Unlimited Bio.
ZAWYA

UAE’s Medcare among first centres outside the US to offer new SMA treatment for patients over two years of age

The newly licensed intrathecal gene therapy, enhances life-changing treatment options for children and families affected by Spinal Muscular Atrophy ...
ZAWYA

Emirates Drug Establishment approves gene replacement therapy for new age group in spinal muscular atrophy patients

Dubai, UAE: The Emirates Drug Establishment (EDE) has announced the approval of Itvisma™ (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular ...
Edex Live on MSN

UAE approves gene replacement therapy for wider SMA age group

The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular atrophy (SMA) ...
Emirates News Agency on MSN

UAE approves gene replacement therapy for new age group in spinal muscular atrophy patients

The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that ...
Khaleej Times on MSN

UAE approves gene therapy for new age group in spinal muscular atrophy patients

The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that ...
Fierce Pharma

ImmunityBio, eyeing broader reach for Anktiva, flexes survival showing in bladder cancer subtype

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)

RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge for an additional indication following successful clinical trials Omisirge now FDA-approved for ...
Agence France-Presse

TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Pha…

Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome ...
News4JAX

From pain to possibility: Curing sickle cell disease

Despite decades of research, the average life expectancy for an American with sickle cell remains about 20 years shorter than ...